Sofosbuvir
| Title | Journal |
|---|---|
| Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. | Drugs 20170701 |
| Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. | The New England journal of medicine 20170601 |
| In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6. | Antiviral therapy 20170101 |
| Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. | The Annals of pharmacotherapy 20160101 |
| Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. | Journal of virus eradication 20160101 |
| Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. | Viruses 20151001 |
| Interferon-free therapy for hepatitis C: The hurdles amid a golden era. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901 |
| Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. | The New England journal of medicine 20150820 |
| Hepatitis C virus: Virology, diagnosis and treatment. | World journal of hepatology 20150608 |
| Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi. | Clinical therapeutics 20150501 |
| Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. | Expert opinion on pharmacotherapy 20150401 |
| Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. | Drugs 20150401 |
| Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. | Lancet (London, England) 20150321 |
| Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. | JAMA 20150301 |
| An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. | Canadian journal of gastroenterology & hepatology 20150101 |
| Changing the face of hepatitis C management - the design and development of sofosbuvir. | Drug design, development and therapy 20150101 |
| Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. | BMC gastroenterology 20150101 |
| Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. | Antimicrobial agents and chemotherapy 20140701 |
| The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. | Antimicrobial agents and chemotherapy 20140601 |
| Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination. | Antimicrobial agents and chemotherapy 20140501 |
| Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase. | Journal of medicinal chemistry 20140313 |
| Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. | Hepatology (Baltimore, Md.) 20140201 |
| Sofosbuvir for the treatment of hepatitis C virus. | Expert opinion on pharmacotherapy 20140101 |
| Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. | Antimicrobial agents and chemotherapy 20130301 |
| Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. | Antimicrobial agents and chemotherapy 20120601 |
| Interferon free hepatitis C treatment regimens: the beginning of another era. | Current gastroenterology reports 20120201 |
| Treatment of chronic hepatitis C--are interferons really necessary? | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| What's new in HCV genotype 2 treatment. | Liver international : official journal of the International Association for the Study of the Liver 20120201 |
| Trial watch: an all-oral and interferon-free future for HCV therapy? | Nature reviews. Drug discovery 20111201 |
| Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938. | Nucleosides, nucleotides & nucleic acids 20111101 |
| Synthesis of diastereomerically pure nucleotide phosphoramidates. | The Journal of organic chemistry 20111021 |
| The HCV NS5B nucleoside and non-nucleoside inhibitors. | Clinics in liver disease 20110801 |
| Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. | The Journal of biological chemistry 20101105 |
| Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. | Journal of medicinal chemistry 20101014 |
| Genetic diversity and evolution of hepatitis C virus--15 years on. | The Journal of general virology 20041101 |
| Side effects of alpha interferon in chronic hepatitis C. | Hepatology (Baltimore, Md.) 19970901 |